We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Testing for Ceramides Helps Predict Cardiovascular Events

By LabMedica International staff writers
Posted on 23 Mar 2017
Print article
Image: Researchers are using plasma ceramides as a new biomarker of unstable atherosclerotic cardiovascular disease (Photo courtesy of the Mayo Clinic).
Image: Researchers are using plasma ceramides as a new biomarker of unstable atherosclerotic cardiovascular disease (Photo courtesy of the Mayo Clinic).
Researchers have found that measuring blood concentrations of the ceramides class of lipids can help predict high risk of cardiac events even for people with low LDL or no evidence of heart blockages, thus helping clinicians identify individuals with suspected coronary heart disease.

Although previous research has shown elevated ceramide levels among people with confirmed heart disease or post-heart attack, this is the first study to show its predictive power among people with no blockages and in those with healthy low levels of low-density lipoprotein (LDL). It showed that ceramides could predict major cardiovascular events—heart attack, stroke, revascularization (procedure to open blocked arteries), and death. Individuals with the highest levels of blood ceramides were found to have a 3-4 fold greater risk of suffering a cardiovascular event compared with those with the lowest ceramide score, regardless of LDL level or presence of a blockage in heart arteries.

“Measuring ceramides in the blood appears to be a new, potentially better marker than LDL in predicting first and repeat cardiac events,” said study lead-author Jeff Meeusen, PhD, Mayo Clinic, offering “another piece of information to help identify individuals who might need a little more attention, guide treatment decisions, and keep patients motivated.”

Dr. Meeusen said that unlike cholesterol, which is fairly inert, acting like a clog in the arteries, ceramides play an active role in the cardiovascular disease process by attracting and drawing inflammatory cells and promoting clotting. All cells have the ability to make ceramides, but ceramides tend to accumulate in blood when we have too much fat or consume excess calories.

The study included 499 patients at Mayo Clinic who were referred for coronary angiography to check for possible blockages in the heart’s arteries, of which only 46% were found to have evidence of a blockage. Patients were grouped into four categories according to their blood ceramide levels - low, intermediate, moderate, or high.

Participants were prospectively followed for an average of 8 years. Overall, 5.1% of patients had a major cardiovascular event during the study timeframe. However, the risk of having an event was progressively higher as ceramide levels increased: for each 1-point increase in the ceramide score, risk rose by 9%—even after fully adjusting for other risk factors (including age, sex, high blood pressure, smoking, total cholesterol, HDL and markers of inflammation). The rate of events was double among people with the highest ceramide score compared with those with the lowest. Total cholesterol also increased with rising ceramide scores, and males were less likely to have high levels of ceramides.

Among those without coronary artery disease upon angiography, the rate of cardiovascular events was only 3.1%. But those with the highest levels of ceramides were 4 times more likely to have an event compared with those with the lowest levels. A similar trend was seen among people with low LDL levels (<100 mg/dL).

“Ceramides continued to be significant and independently associated with disease even after adjusting for traditional and novel cardiovascular risk factors,” said Dr. Meeusen. Cardiologists at Mayo Clinic are already routinely checking ceramides using the new test released in August 2016 as a way to further risk-stratify patients. And “knowing their ceramide score can improve therapeutic compliance and patient motivation, particularly since the numbers improve within a few weeks,” he said.

The new test is available through Mayo Medical Laboratories. The present study is the first to test its clinical utility. Dr. Meeusen presented the study “Plasma Ceramide Concentrations Predict Risk of Cardiovascular Events” at ACC’s 2017 Annual Scientific Session (Washington, DC, USA; March 17-19).

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
New
Lyme Disease Test
Lyme IgG/IgM Rapid Test Cassette

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.